Clinical trials are growing rapidly as a care option, and for good reason. They’re literally saving lives. They’re growing so much, in fact, that there is now a pre-clinical or clinical trial treating almost any kind of disease. But, as with any industry, some providers are more reputable than others. And because TrialSite News puts transparency first, we’re sharing consumer-centric information on a variety of clinical investigation sites. So, as part of our ongoing research effort to bring these research sites to life, we’re covering Benchmark Research of the hyperCORE Network.
The hyperCORE clinical research network was covered by TrialSite News back in April 2019. A “Super Network” of highly awarded and experienced Clinical Research Site Organizations, it forms “the second largest site network in the world with more than 80 sites across 5 countries on 2 continents,” according to their recent press release. hyperCORE reports that eight different independent research site companies have come together under one umbrella, focusing on agility and innovation to accelerate clinical research through centralization of core operations and innovative strategic partnerships with Sponsors/CROs. Benchmark Research is one of those eight.
Benchmark Research is an independent company and leader in the clinical research industry with experience in Phase I-IV trials. This makes them a target for private-equity buy out, but they’ve remained independently owned. This could represent a pro or a con depending on philosophy. On the pro side, they may have more autonomy and flexibility to do what they think is right for their business. On the con side, they may have less capital to fuel growth and investment, for example.
Benchmark has six geographically diverse, multi-therapeutic research centers. Their database of over 90,000 patients gives hyperCORE access to a large number of subjects, ensuring high volume patient recruitment and retention. They’ve enrolled over 40,000 subjects in more than 1,025 trials since their inception in 1997.
Benchmark’s trial experience covers a wide range of indication areas, including diagnostics, cardiovascular, infectious disease, musculoskeletal, endocrinology, women’s health, allergy and vaccines. They have conducted trials with 100+ Sponsors, providing them with unsurpassed trial execution, clean data, and a steadfast pledge to patient safety.
Established in 1997, they have impressive experience and leadership. “This is the network of networks – a first of its kind,” said Mark Lacy, CEO of Benchmark research and CEO of hyperCORE. “This is the realization of a vision several years in the making. I wanted to bring together a group of already highly successful and professionalized research site businesses in a new and powerful way. The magic lies within the mutual ownership model. This motivates and ensures we each bring the best to the table and work together in ways not possible before. Together, we can push the boundaries, leading the drive for further innovation, something that will resonate across the clinical research industry. By banding together in such an intimate and integrated way, we can accelerate the entire end to end process from feasibility to close-out. It’s research accelerated!”
For the fifth time in seven years, Benchmark Research was named Best Clinical Trial Site or Network at the 2018 Vaccine Industry Excellence Awards, presented at the annual World Vaccine Congress in Washington, DC.
Benchmark Research has treated over 35,000 patients and participated in many hundreds of major clinical trials—they have done so all while maintaining what appears to be a solid track record for quality oversight. They appear to be a well-run, disciplined business as well.
Benchmark endorses their principal investigators, saying on their website that “Each Investigator participates in Benchmark’s ongoing internal investigator training program. Our investigators go the extra mile to ensure smooth conduct of your clinical trial. In addition to protocol-specific responsibilities and GCP/FDA requirements, you can count on our doctors to attend investigator meetings, actively recruit patients from their private practice, meet with CRAs during monitoring visits and offer qualitative feedback regarding your clinical trial. All of our investigators share the goal of providing you with accurate, high-quality data.”
- Dr. Laurence Chu, Principal Investigator, Austin, TX
- Dr. William Seger, Principal Investigator, Fort Worth, TX
- Dr. Michael Cotugno, Principal Investigator, New Orleans, LA
- Dr. Darrell Herrington, Principal Investigator, San Angelo, TX
- Dr. Greg Hachigian, Principal Investigator, Sacramento, CA
- The PI for their San Francisco location was not listed, and there are no current studies are being conducted there currently
How did benchmark get their research sites?
Benchmark International has successfully facilitated the acquisition of Comprehensive Clinical Trials, LLC and Advanced Clinical Trials, LLC (hereinafter referred to as CCT) by Vitalink Research, LLC. (hereinafter referred to as Vitalink).
CCT is an accomplished clinical research site specializing in conducting Phase II – IV clinical trials. It serves over 400 sponsors ranging from small biotech companies to the world’s largest pharmaceutical and medical device companies and has completed hundreds of trials.
Vitalink is a US network of fully integrated clinical trial sites, connects world-class physicians and medical professionals with site managers and research coordinators to set the standard for the timely execution of clinical trial protocols with trustworthy results across all sites.
All of the clinical investigators found on the FDA’s clinical investigator database had No Action Indicated or NAI classifications, meaning no objectionable conditions or practices were found during the inspection.
According to their Google Listings, Benchmark’s study sites in Austin, New Orleans, Sacramento, Fort Worth, San Angelo, and San Francisco all have positive online reviews. Their facebook page, and their Sacramento and Fort Worth yelp pages did not have any reviews.
Call to Action: Follow our Daily Digest to learn more about hyperCORE’s other research sites.Source: